05.06.2013 - After having raised €19m, Belgian reg-med specialist Cardio3 BioSciences has hunger for more. The company announced to go public.
Only two weeks after a capital increase, the company said it will launch an IPO at NYSE Euronext Brussels and NYSE Euronext Paris to raise new funds. Cardio3 BioSciences' lead product C-CureR (C3BS-CQR-1) has been moved to Phase III development following promising results.
Through a process called cardiopoiesis, the company can reprogramme bone marrow cells to become heart precursor cells. Cardio3 BioSciences wants to use them to repair heart failure secondary to ischemic heart disease. The IP was licenced from the US Mayo Clinic (Rochester, Minnesota).
Heart failure is one of the world's greatest unmet medical needs. At 40 years old, a person has a one in five risk of developing heart failure and, once the disorder is apparent, a one in three chance of dying within a year of diagnosis. US$32bn annually is spent on heart failure patients in the US alone.
C3BS-CQR-1 is currently being tested in Europe in the CHART-1 trial, the world's first phase III trial using pre-programmed cardiac progenitor cells for the treatment of heart failure. Phase II results pointed to an increase of 25% of the Left Ventricular Ejection Fraction (LVEF) which was statistically significant (p<0.0001), as was the increase in exercise capacity measured by the 6 minutes Walking Distance test (+77m change at 6 months versus baseline in comparison to the control group (p<0.01). Cardio3 BioSciences intends to start a trial in the US (the CHART-2 trial if the FDA authorizes its start. The CHART programme is designed as two pivotal studies to obtain marketing authorisation in Europe and in the USA respectively, either alone, or in combination with other clinical trials.
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more